Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Doximity

Doximity, Inc. develops an online healthcare resource and interactive platform. The Company cloud-based platform enables its members to collaborate with their colleagues, securely coordinate patient care, and conducts virtual patient visits. Doximity serves customers in the United States.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Doximity surpasses Q4 revenue expectations and eyes continued growth

Doximity's Q4 2023 performance exceeded expectations, showcasing strong financial metrics and strategic investments. The company's outlook for Q1 2024 indicates continued growth, with a focus on topline expansion and product innovation. While facing challenges in pricing strategies and competitive landscape, Doximity is well-positioned to capitalize on opportunities in the healthcare technology sector.

Doximity reports strong Q1 results but lowers 2024 guidance

Doximity delivered strong financial performance in Q1, but challenges in upsell close rates led to a downward revision in annual guidance. The company's focus on innovation, expansion, and shareholder value, along with a cautious outlook for the remainder of the year, presents a mixed picture of opportunities and challenges for investors.

Doximity reports strong Q3 earnings, eyes growth amid product challenges

Doximity's Q3 performance demonstrated resilience and growth potential despite challenges in meeting annual guidance due to product delays.
The company's focus on innovation, strong client relationships, and strategic investments position it well for future growth and market leadership.
With a commitment to R&D, expanding product offerings, and maintaining pricing discipline, Doximity aims to capitalize on opportunities and navigate challenges for sustained success.

Doximity surpasses Q4 revenue targets, poised for growth and innovation

Doximity's Q4 performance exceeded expectations, with robust revenue growth, strong margins, and strategic investments in new products and talent.
While facing challenges like flat growth in certain segments and pricing adjustments, the company is well-positioned to capitalize on opportunities in network expansion and technology innovation.
With a focus on enhancing user experience, driving engagement, and optimizing revenue streams, Doximity is poised for continued success and value creation for shareholders.
The company's financial health, innovative product offerings, and market positioning indicate a promising outlook for sustained growth and competitive advantage in the healthcare technology sector.

Doximity surpasses Q1 revenue expectations, faces upsell challenges

Doximity's Q1 performance was strong, but challenges in upsells prompted a staff reduction and revised guidance. The company is optimistic about long-term growth, leveraging new products and a self-serve ad platform for future success.

Doximity beats Q2 expectations, eyes growth amidst market uncertainties

Doximity's strong Q2 performance exceeded revenue and EBITDA guidance, driven by record physician engagement and new product success.
While facing market uncertainties and competition challenges, the company sees opportunities in pricing strategies and continued growth.
Investments in high-touch services, Telehealth, and video products are paying off, with a focus on enhancing client offerings.
Integration with IQVIA for real-time ROI analysis positions Doximity for future growth and client value creation.

Doximity beats Q3 revenue, eyes growth through AI products

Doximity's Q3 performance exceeded expectations with strong revenue and margin growth. The company faces challenges with elongated sales cycles but has opportunities for growth through AI products and new modules. Overall, Doximity's competitive position remains strong in the market.

Doximity exceeds Q4 revenue, eyes mid-teens growth post-COVID

Doximity's Q4 earnings call highlighted strong financial performance, customer satisfaction initiatives, and growth opportunities in digital marketing and new business segments. While facing challenges in growth slowdowns and market uncertainties, the company is leveraging strengths in optimized margins, visibility into revenue guidance, and customer commitment to drive future success.

Doximity excels in Q1 2025, driving growth through client value

Doximity's Q1 2025 performance reflects strong revenue growth, operational efficiency, and client value proposition.
The company's focus on innovation, customer engagement, and strategic insights positions it well for sustained growth.
Despite challenges, Doximity's proactive approach to industry dynamics and growth opportunities bodes well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

RADNOR, Pa. , April 18, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) ("Doximity" or the "Company") on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the "Class Period").

Class Action Announcement (DOCS): Kessler Topaz Meltzer & Check, LLP Has Filed A Securities Fraud Class Action Lawsuit Against Doximity, Inc.

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Doximity business and prospects, resulting in its stock trading at inflated prices.

DOCS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Doximity, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against Doximity, Inc. (NYSE: DOCS) (“Doximity” or the “Company”) on behalf of investors who purchased or acquired Doximity common stock between February 9, 2022, and April 1, 2024, inclusive (the “Class Period”). This action, captioned Kissler v. Doximity, Inc., et al., Case No. 3:24-cv-02281 was filed in the United States.

Investor Alert: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Doximity, Inc. and Encourages Investors With Losses to Contact the Firm (NYSE: DOCS)

Surgery Partners

Investors interested in stocks from the Medical Services sector have probably already heard of Surgery Partners (SGRY) and Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks?

SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?

LOS ANGELES, CA / ACCESSWIRE / April 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Doximity, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Doximity investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws,.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Doximity, Inc. (DOCS) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS) investors concerning the Company's possible violations of federal securities laws. On April 1, 2024, Jehoshaphat Research published a report alleging, among other things, that “Doximity's underlying sales . . . are declining at a negative -3-6% rate, but that this decline has been masked through accelerated revenue recognition.” On this.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Doximity, Inc. (DOCS) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / April 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Doximity, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 1, 2024, Jehoshaphat Research published a report alleging, among other things, that “Doximity's underlying sales . . . are declining at a negative -3-6% rate, but that th.

The Law Offices of Frank R. Cruz Announces Investigation of Doximity, Inc. (DOCS) on Behalf of Investors

The heavy selling pressure might have exhausted for Doximity (DOCS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -6.99% in 4 Weeks, Here's Why You Should You Buy the Dip in Doximity (DOCS)

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Doximity, Inc. (NYSE: DOCS) resulting from allegations that Doximity may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Doximity securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Inquire About Securities Class Action Investigation – DOCS

Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Doximity (DOCS) Rating Upgrade to Buy

NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Doximity, Inc. ("Doximity") (NYSE:DOCS) concerning possible violations of federal securities laws. On May 16, 2023 Doximity announced it was revising downwards its guidance for 2023.

Levi & Korsinsky Reminds Shareholders of an Investigation into Doximity, Inc. (DOCS) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Doximity, Inc. ("Doximity") (NYSE:DOCS) concerning possible violations of federal securities laws. On May 16, 2023 Doximity announced it was revising downwards its guidance for 2023.

Levi & Korsinsky Reminds Doximity Investors of the Ongoing Investigation into Potential Violations of Securities Laws - DOCS

NEW YORK, NY / ACCESSWIRE / March 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Doximity, Inc. ("Doximity") (NYSE:DOCS) concerning possible violations of federal securities laws. On May 16, 2023 Doximity announced it was revising downwards its guidance for 2023.

Doximity Being Investigated on Behalf of Doximity, Inc. Investors. Contact Levi & Korsinsky For Details

LOS ANGELES, CA / ACCESSWIRE / March 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or "the Company") (NYSE:DOCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Doximity, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Doximity, Inc. ("Doximity") (NYSE:DOCS) concerning possible violations of federal securities laws. On May 16, 2023 Doximity announced it was revising downwards its guidance for 2023.

Investors who lost money on Doximity, Inc. should contact Levi & Korsinsky about an ongoing investigation - DOCS

NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Doximity, Inc. ("Doximity") (NYSE:DOCS) concerning possible violations of federal securities laws. On May 16, 2023 Doximity announced it was revising downwards its guidance for 2023.

Doximity, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - DOCS

ICON

Investors with an interest in Medical Services stocks have likely encountered both Icon PLC (ICLR) and Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks?

ICLR vs. DOCS: Which Stock Is the Better Value Option?

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Doximity, Inc. ("Doximity") (NYSE:DOCS) concerning possible violations of federal securities laws. On May 16, 2023 Doximity announced it was revising downwards its guidance for 2023.

Doximity, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - DOCS

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Doximity, Inc. ("Doximity") (NYSE:DOCS) concerning possible violations of federal securities laws. On May 16, 2023 Doximity announced it was revising downwards its guidance for 2023.

DOCS ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Doximity, Inc.

NEW YORK, NY / ACCESSWIRE / March 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Doximity, Inc. ("Doximity") (NYSE:DOCS) concerning possible violations of federal securities laws. On May 16, 2023 Doximity announced it was revising downwards its guidance for 2023.

DOCS STOCK ALERT: Levi & Korsinsky Notifies Doximity, Inc. Investors of an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Doximity, Inc. ("Doximity") (NYSE:DOCS) concerning possible violations of federal securities laws. On May 16, 2023 Doximity announced it was revising downwards its guidance for 2023.

Investors Who Lost Money On Doximity, Inc. Should Contact Levi & Korsinsky About An Ongoing Investigation - DOCS

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Doximity, Inc. ("Doximity") (NYSE:DOCS) concerning possible violations of federal securities laws. On May 16, 2023 Doximity announced it was revising downwards its guidance for 2023.

Doximity, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - DOCS

NEW YORK, NY / ACCESSWIRE / March 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Doximity, Inc. ("Doximity") (NYSE:DOCS) concerning possible violations of federal securities laws. On May 16, 2023 Doximity announced it was revising downwards its guidance for 2023.

News for Doximity Stock (DOCS)